Mirae Asset Global Investments
CPRX

Mirae Asset Global Investments’s Catalyst Pharmaceutical CPRX Stock Holding History

Mirae Asset Global Investments’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-57,167
Closed -$930K – 1743
2024
Q1 		$930K Sell
57,167
-7
-0% -$105 ﹤0.01% 1582
2023
Q4 		$961K Sell
57,174
-1,702
-3% -$23.3K ﹤0.01% 1639
2023
Q3 		$688K Sell
58,876
-8,035
-12% -$107K ﹤0.01% 1731
2023
Q2 		$901K Buy
66,911
+6,847
+11% +$98.5K ﹤0.01% 1626
2023
Q1 		$996K Buy
60,064
+18,875
+46% +$311K ﹤0.01% 1549
2022
Q4 		$766K Buy
41,189
+1,347
+3% +$20.7K ﹤0.01% 1652
2022
Q3 		$511K Buy
39,842
+12,240
+44% +$145K ﹤0.01% 1854
2022
Q2 		$193K Buy
+27,602
New +$202K ﹤0.01% 2153

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Mirae Asset Global Investments's CPRX Position: Q2 2024 in Review

Mirae Asset Global Investments sold out of Catalyst Pharmaceutical (CPRX) in Q2 2024, closing a stake of 57,167 shares — an estimated $930K sold.

Mirae Asset Global Investments first reported a position in CPRX in Q2 2022 and held it in 8 quarters. The position peaked at $996K in Q1 2023. 271 funds tracked by Wall St. Rank hold CPRX as of Q2 2024.

  • Mirae Asset Global Investments reported no remaining Catalyst Pharmaceutical position as of Q2 2024 after selling out during the quarter.
  • Mirae Asset Global Investments sold 57,167 Catalyst Pharmaceutical shares in Q2 2024, an estimated $930K.
  • Mirae Asset Global Investments first reported a position in Catalyst Pharmaceutical in Q2 2022 and held it in 8 quarters.
  • Mirae Asset Global Investments's Catalyst Pharmaceutical position peaked at $996K in Q1 2023.
  • 271 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2024.

Based on Mirae Asset Global Investments's 13F filing for Q2 2024, filed 30 Jul 2024.